Abhijit Bhattacharya - Executive Vice President of Investor Relations François Adrianus van Houten - Chairman of the Board of Management, Chief Executive Officer, President and Chairman of The Executive Committee Ron H. Wirahadiraksa - Chief Financial Officer, Executive Vice President, Member of Board of Management and Member of The Executive Committee

Andreas P. Willi - JP Morgan Chase & Co, Research Division Martin Wilkie - Deutsche Bank AG, Research Division Ben Uglow - Morgan Stanley, Research Division Gael de-Bray - Societe Generale Cross Asset Research Olivier Esnou - Exane BNP Paribas, Research Division Simon Toennessen - Crédit Suisse AG, Research Division Fredric Stahl - UBS Investment Bank, Research Division Aaron Ibbotson - Goldman Sachs Group Inc., Research Division Daniel Cunliffe - Nomura Securities Co. Ltd., Research Division Philip Wilson - Redburn Partners LLP, Research Division William Mackie - Berenberg, Research Division Andrew Carter - RBC Capital Markets, LLC, Research Division Mark Davies Jones - Agency Partners LLP

Welcome to the Royal Philips Third Quarter Results 2013 Conference Call on Monday, 21st of October 2013. [Operator Instructions] Please note that this call will be recorded and is available by webcast on the website of Royal Philips. I will now hand the conference over to Mr. Abhijit Bhattacharya, Head of Investor Relations. Please go ahead, sir.

Good morning, ladies and gentlemen. Welcome to this conference call on the results for the third quarter of 2013 of Royal Philips. I am here with Frans van Houten, our CEO; and our CFO, Ron Wirahadiraksa. In a moment, Frans will make his opening remarks and give you an update on the progress we've made during the quarter. Ron will shed more light on the details of the financial performance during the quarter. After this, both Frans and Ron will be happy to take your questions. As usual, our press release and the accompanying information slide deck were published at 7 a.m. CET this morning. Both documents are now available for download from our Investor Relations website. We will also make available a full transcript of this conference call available on the Investor Relations website by tomorrow. And with that, let me hand the call over to Frans. François Adrianus van Houten: Thanks, Abhijit. Welcome, and thank you, all, for joining us today on this call. This was another quarter of solid progress for Philips. Despite challenging economic conditions, I am particularly pleased that our operational results improved by 33% compared to the third quarter of last year. All sectors achieved a year-on-year improvement in operational results, thanks to our Accelerate! program. Our focus on operational excellence has led to a better operational gross margin, which are up by 240 basis points compared to a year ago. The global economy, however, continues to impact our business. As we communicated to you at the beginning of the year, we expected a slow start of 2013, and that was indeed the case. We originally expected conditions in North America and Europe to improve as the year would progress, leading to a stronger second half of the year. Unfortunately, this was not the…

Thank you, Frans. Good morning, and welcome to all of you on the call. I will begin by giving you some color on the developments in the markets we serve and then walk you through the financial performance for the third quarter. Let me start with Healthcare, where the U.S. government shutdown further added to the uncertain environment, which is likely to cause delays in purchasing decisions. We expect the related market uncertainties to continue into the next month. Healthcare construction is forecasted to decline by 2% in 2013, and patient procedure volume growth expectations remain unchanged in the low-single-digit range. In Europe, the Healthcare market remains soft in most countries, including in larger markets such as Germany and France. We expect that this trend will not significantly change for the remainder of the year. In the growth geographies, the ASEAN region is expected to come in at a mid-single-digit growth rate, and China continued to show solid growth during the third quarter of 2013. On the other hand, Middle East and Turkey is expected to come in at the same level as last year. Russia continued to have low tender activity, which resulted in low market momentum in the third quarter. Overall, we estimate the Healthcare market growth to be in the low-single-digit range for the whole year. The consumer markets in Q3 continued to follow the fluctuating patterns seen in the overall economy. Eurozone real GDP growth continues to show a weak trend. Unemployment remains high at 12%, with Spain and Greece's unemployment rates still over 26%. The EU consumer confidence index has been improving since January 2013, with Germany poised for modest economic growth. Total retail sales volume shows an increasing year-over-year trend since the beginning of 2013. The U.S. picture for consumer markets improved during Q3,…

[Operator Instructions] The first question comes from Andreas Willi from JPMorgan. Andreas P. Willi - JP Morgan Chase & Co, Research Division: My 2 questions are -- the first one, you mentioned in your comments just now that you expect low-single-digit growth for your Healthcare business for this year. I just wanted to clarify that -- is this an underlying sales number? And if so, it implies quite a strong Q4, given that year-to-date you are slightly negative. Second question on restructuring, you spent a bit less in Q3. Also, the guidance for Q4 is a bit below what I had in the model. Is it that you can do more with less money? Is it a timing difference with more charges next year? Or are you just needing less restructuring, which would be surprising given that the top line outlook hasn't improved? François Adrianus van Houten: Thank you, Andreas. Actually, I don't think in the text that we talked about the sales growth in Q4, but obviously, Q4 is always a big quarter for us. We have reiterated that we intend to make our 2013 midterm targets for the whole group, which, if you do the math, also implies that we intend to grow, for the group again, sales on a comparable basis in Q4 in order to reach that target. I think that's about as much as we can say about it, Andreas, as we don't give specific guidance by sector, and certainly not for the coming quarter. Maybe I can ask Ron to take the second point on the cost side.

Yes. So indeed, Andreas, we needed somewhat lesser restructuring. As you know, we always have to take [ph] restructuring provisions, including everything. And as we sometimes move towards better solutions, people find employment elsewhere or through other methods, we seldomly use the whole restructuring provision. So there is some of an effect in there. It doesn't mean that we have slowed down the restructuring effort that we need to make, and this particularly pertains, of course, also to the industrial footprint in Lighting for which we have taken main provisions last year. It's more that we're not disbursing on those provisions in this year, in other words paying out on monies to take into the P&L last year. So there is no backlog. We simply need a little less, but it's fully in line with the plans that we're having and we're executing on. Your previous point on Q4, yes, the assumption is, indeed, that Q4 for Healthcare will be a better quarter than we have seen year-to-date, and that is always an event [ph], as Frans said, in the seasoning of the Healthcare sales. So that is correct.

The next question comes from Martin Wilkie from Deutsche Bank.

It's Martin from Deutsche Bank. A couple of questions. Firstly, on Lighting, a very strong margin improvement there. You have called out 2 or 3 areas that drove that, but in particular, I think Lumileds was one area where you'd always talked about an improvement going into the end of the year. Was that the largest part of that margin effect? Or perhaps you could just give a little bit more detail on the margin uplift in Lighting. And the second question was on corporate costs. It's tracking lower than I'd expected, I think lower than your guidance rate. Just to sort of let us know what are you expecting for the corporate cost outlook for the remainder of the year and into next year.

Okay. Martin, thanks for the questions. Yes, as I said earlier, Lighting is really a mix improvement story. We have grown in Lighting. We're very pleased by that, the 3% comparable sales growth. It's mainly that Lumileds and PLS have improved. Particularly for PLS, in Q3, the situation in Europe has improved, and we have reaped the benefits of that. This is, of course, a mix that is not a mix on a constant-cost basis. This is mixed improvement that also has in it the improvement that we're making in Accelerate!, so driving better bill of material costs and keep taking overhead costs out while keep on investing in growth for Lighting. Your second question...

Corporate cost.

Was on the corporate cost. Yes, so we had somewhat lower litigation costs, as I said, but somewhat higher royalty income than anticipated. These things sometimes go in a little bit lumpy or chunky, maybe that's the right word. For the full year, we're staying very close to the guidance that I gave earlier. I would put it at EUR 290 million for the year, Martin.

The next question comes from Ben Uglow from Morgan Stanley.

I had a couple of questions, I guess, mainly about the Healthcare business. I mean, first of all, could we just step back a little bit and ask, given the events in Washington over the recent weeks, how does this generally impact your business when you look forward and you think about reimbursement rate factors, et cetera? Could we be moving into a slightly better environment early next year? How are you interpreting things in the U.S. market right now? Specifically, when we also look at order rates for the fourth quarter, should we assume that there is going to be a catch-up effect from the EPIQ ultrasound business? Or should that sort of dampening effect in the third quarter reverse a little bit in the fourth quarter? And finally, just to confirm, on the patient care business, which was down 7%, that sounds to me like that's all just the comparable order effect. So there is no significant changes in market share in Patient Care. So those were my questions. François Adrianus van Houten: All right, Ben, great set of questions, and let's take them in stride and one by one. The first one is not easy. The recent events in Washington are not the complete story, it's the whole healthcare reform that is affecting the U.S. healthcare business. We see, on a large scale, hospitals merge into larger IDNs and accountable care organizations, with an expectation that, eventually, there will be maybe 400 large systems. And the consolidation of the U.S. healthcare providers will -- is distracting, so to speak, healthcare CEOs. They are focused on that consolidation and also to understand the changes in reimbursement that are happening, and it takes the urgency away from investing in new equipment. Now -- and I think that uncertainty will…

The next question comes from Gael de-Bray from Societe Generale.

My question actually relates to your marketing and selling strategy. What's driving the 9% decline in selling expenses in Q3 this year versus last year? And maybe which divisions have seen the biggest decline in terms of selling expenses during the quarter? And the question related to that is, is it really sustainable? I mean, will you need, at some stage, to increase selling expenses again so as to reignite growth maybe in some of your businesses that are not growing that much so far, like Healthcare and part of Lighting? François Adrianus van Houten: I think, Ron, will you take this one?

Okay. So a part of that is, of course, currency, as we -- you have seen that we have communicated the 600 basis swing in the top line, minus 3 nominal, 3 on a comparable basis. And an offsetting effect, of course, takes place in the cost, but it is definitely also productivity. And of course, through lower nominal sales, we are ongoing our -- driving our costs to the right levels of sales. We're very pleased in doing that, so that's why compares with gross margin improvement. Also through the FX, as Frans mentioned earlier, we've also been able to manage our cost. So some ForEx, some productivity. And where there's lower top line growth, we simply adjust our cost base. François Adrianus van Houten: Maybe, Gael, then reflecting your second part of the question, which was more longer-term, forward-looking, of course, there, I'd like to take you back to the Capital Markets Day in London, where we outlined that, from -- for the next 3-year period till 2016, we expect to drive 300 to 400 basis points of productivity improvement, building on what Ron just said. But at the same time, we will invest approximately 200 basis points, some of which will go to additional innovation and also unlocking further growth. All in all, we will, on a very granular level, drive operational leverage, driving better return on sellex. But in some markets where we see massive growth opportunities, such as, for example, Africa, Southeast Asia, Mexico, net-net, we will probably increase selling expenses. So this whole granular approach that we introduced already in 2011 is now paying us dividends where it's -- becomes much more a surgical instrument and not a across-the-board investment business [ph].

So maybe I can add a little data point to this, because we keep reading that we make our results through cutting cost. Well, Accelerate!, as you know, it's a much larger program than just cutting costs. It's a transformational program with the 5 key work streams, and I want to elaborate on -- in this question. What I do want to say is that if you look at our currency-comparable development of our sellex in our R&D, so our go-to-market innovation, we can safely say that, for the year-to-date number, we had a, what, close to 6% CAGR in those costs, and R&D is even higher, 9%. So it's certainly not so that we are holding back on investing in strategic growth initiatives and our go-to-market infrastructure. I just wanted to share that with you.

The next question comes from Olivier Esnou from Exane.

The first question would be on the objective to grow 4% top line over the 3-year period, if we go back to the incentives system. I just want to make sure I get the math right. Will you just take the organic growth as reported by the group over the period, or will you deconsolidate AVM for the 3 years? How does that work? Implicitly, what I'm just trying to get is what you need in Q4, according to your own estimates. Second question is on foreign exchange. Can you remind us of the sensitivity of margin to FX? And I know you're hedged, so you may not have the impact this quarter, but is there any sort of implied impact now due to currencies that will materialize over the coming quarters? And lastly, on inventories, they were going up a little bit. I just wanted to know what's driving that going into Q4? You're confident with the level you have right now.

Okay, on your last point, I don't think our inventories went up, neither nominally or as a percentage of MAT sales. So 40 basis points down. If you look at Page 20 of the press release, you can see that, as a percentage and as a nominal amount, they both went down, EUR 3,877 million in January-September 2012 to EUR 3,832 million. So that is that point. On the incentives, we have a comparable sales growth CAGR, as you know, as we always report, from 2011. So the 4% to 6% comparable sales growth for the incentive, the Accelerate! incentive, is on a comparable sales growth CAGR. And we do believe that, as we also said, that we will be able, despite all these headwinds, to make this target. François Adrianus van Houten: That excludes AV in the comparison -- comparables.

Yes. So comparable is excluding ForEx and portfolio changes...

So it excludes AVM for the 3 years, or just for this year?

No, no, for the whole period, because you make the financials comparable. So what we now report on, as I've said, is with the audio, video, multimedia in discontinued operations, so they're out.

So it's fair to say don't really need organic growth even in Q4 to make it now...

Oh, we do need organic growth in Q4. I wish I could agree with you. But no, there's still a lot of effort needed to make the target. It's by no means a walk in the park.

Okay. And the next one?

Yes, on ForEx sensitivity, well, we have said, as I've just also outlined, it's about 600 basis points impact in the top line. We don't give out how much it has impacted the bottom line. So with that, you can also see it's not been a devastating impact. But there is, of course, quite an impact that we have been able to offset through our normal hedging policies, but also through more active management and proactive management of pricing and taking costs out. So it's hedging and, let's say, the normal operational management that you do with the ForEx exposure. We are structurally long in dollars. And almost all currencies, as you know, have been depreciating versus the euro, and that is another good thing for us. So we don't want to also, let's say, make an excuse for headwind. And it has -- yes, of course, in the second half, as we said, the ForEx headwinds will -- would increase also for Q4, but that we expect, with current information, to be able to withstand.

The next question comes from Simon Toennessen from Crédit Suisse. Simon Toennessen - Crédit Suisse AG, Research Division: Two questions from my side. The first one is on the Healthcare business, and particularly Imaging Systems. You had a high-single-digit declines in terms of sales growth in the first half, and now you're flagging mid-single-digit declines in Q3. Obviously, you know your order book pretty well. When do you think is the sort of the earliest when you expect the Imaging Systems business to return to growth? Obviously, you're still seeing declines in the order book now, but are we talking, if it doesn't get worse from Q4 on, kind of to Q2, Q3 next year? Or what are your expectations there? And the second question is on Lighting. You flagged, Ron, a bit about the geographical performance already, but could you just maybe give us growth rates of your European and the U.S. business, and also what you're seeing in Asia?

To start with the last part, do you mean for the group or for Healthcare? So... François Adrianus van Houten: Lighting, Lighting. Simon Toennessen - Crédit Suisse AG, Research Division: Lighting, Lighting growth.

Okay, well, we'll get you that. Do you want to comment on image... François Adrianus van Houten: Yes, well, maybe while you look up the Lighting growth rates, Ron. And then on imaging, we can be relatively short. It is an uncertain market. We are working hard with very competitive products to improve our position, but at this time, the outlook remains uncertain, so we cannot yet give you a strong prediction when that growth rate is back into the positive territory.

Okay. Then the comparable sales growth for Lighting for Q3. As you know, the overall sales growth were 3%; Western Europe, minus 2%; North America, minus 3%; other mature, minus 16%; and the growth geographies, 12%.

And the next question comes from Fredric Stahl from UBS.

It's Fredric here, from UBS. Could I ask you -- on the Healthcare side in emerging markets, obviously, the orders were a bit weaker there in the quarter. Is that just due to the normal lumpiness of the business? Or do you see signs that the emerging markets, the volatility we've seen in currencies, for example, are impacting confidence amongst your customers? Then I have 2 questions on Lighting as well. I was wondering if you could give us an update on the gross margin performance, the difference between LED and the traditional lighting margins or product margins. And then finally, do you think that your performance, the mid-single-digit decline that you're seeing in mature geographies, do you think that's in line with the markets? And do you think it's driven by destocking still, partly?

Okay, I think what we see happening in the mature markets and in Europe is in line with the markets, so no specific destocking that we are currently aware of. Again, really very positive about -- particularly towards the end of the quarter, where the sales resumed and are better paced than we had earlier experienced, so that is very good. Healthcare in emerging markets, that is mostly China grew, but the Russia tender activity was very low. And in ASEAN, you've experienced a pushout of some of the orders. And if you look at the order intake, the Indian subcontinent was strong double digits, China was strong double digits. And as I said, Russia and some of the ASEAN, as also mentioned in my speech, were lower, so that caused that. On Lighting, the gross margin improvement, yes, our DfX program, although not very stellar in results contribution, because we're building a funnel for the coming 3 years to deliver the target that we have communicated of EUR 1 billion additional savings, but it does lead to people already doing today, in the normal ongoing, let's say, concept savings in our products, paying more attention and driving costs further down. We have some benefits of the phosphor decline, that is also fair to say. But overall, we're very pleased with the good improvement in the cost of goods, and particularly with raw material for our Lighting business. Also, on your question on LED, the gross margin for LED overall is very close, as we also in our Capital Markets Day communicated, very close to the conventional business.

The next question comes from Aaron Ibbotson from Goldman Sachs.

I had 2 quick questions. The first question relates just to how much remaining cash outflow we should expect from current sort of restructuring charges already taken. I sort of appreciate that there will be more coming from new restructuring. Just if we can get sort of a taking stock of the current situation. And then secondly, I was just hoping -- just a quick follow-up on the question on FX and hedging there, and I appreciate you don't want to go into too much detail on the EBIT sort of bridge. But did you have any negative sort of transaction rather than translation impact in the third quarter? And if not, should we expect this to be sort of concentrated in Q4, Q1? Or roughly where from -- sort of when will we see these hedges roll over to the new FX reality, if I put it that way?

Yes, so Andreas, on your first question, not very specific, but we have said also at the beginning of the year that probably, the disbursement for restructuring, it would be to the tune of EUR 250 million for the full year, around that number. It always goes a little bit lumpy, so we've had that in mind, but that is the order of magnitude. On the ForEx, yes, it's a very good question. Let me also say that in our hedging policy we hedge transaction results. We do not hedge translation results. So most of the impact, actually, that we find back in the P&L is from translation, and that is a matter of fact. And then, as I said, we nevertheless have been able to offset that with other measures, price increases where we can, and taking out cost and, furthermore, the self-help story through Accelerate!. In Q4, we do expect that ForEx impact will be slightly bigger than in Q3. As I've said also, we remain committed to deliver our targets.

But just to clarify, then. So if I look at sort of where you're hedging, generally 3, 6 months. Or is it further? Should we expect sort of the peak impacts to be in the first quarter of next year? Or is that likely, assuming that FX stays flat from here-ish, the peak impact should be in the fourth quarter, if I'm only talking about transaction here, obviously?

Yes, so we hedge our committed exposure 100%. And on a 12-month rolling basis, we hedge our anticipated exposure. That is to a level of 30% to 40%, depending on forecast ability of the business. So yes, at a certain point, of course, we'll run out of hedges. That is fair to say. François Adrianus van Houten: And of course, it depends very much what the dollar will do, right?

But it sounds then that we should expect the biggest impact to be in the first half of '14, assuming flat rates from here, basically.

That's correct. That's right.

The next question comes from Daniel Cunliffe from Nomura.

Just really a follow-up on Lighting. We saw, obviously, a reported 3% growth, LED up 33%, sort of conventional down approximately 10%. That's quite a drag for most of this year, but given the current situation, I mean, if -- just annualizing the sort of current last 6 months gets you to a decline, instead of minus 10%, it's sort of more like minus 3% to minus 5%, but that's a sort of mathematics. I just really want to sort of check that with what's really going on. And in other words, would you expect conventional Lighting to continue at this pace? Or is the slowdown decelerating and we could think more logically about sort of a continued sort of 3% to 5% decline in that going forward?

Yes, so I said in the Capital Markets Day, we see around mid-single-digit decline. Also, year-to-date, if you look at 2013, it is really mid-single digit. It was -- it has been somewhat higher in the first and second -- no, in the second quarter particularly, it was a little bit higher. But yes, then sometimes, this goes a bit chunky also, depending on how the development of sales goes within an otherwise stellarly glowing -- growing, LED business. So Q3 in itself was really mid-single digits, not -- we don't recognize the 10% that you mentioned, unfortunately.

The next question comes from Phil Wilson from Redburn.

It's Phil Wilson here, from Redburn. Two questions, please. Firstly, a question really on price. Can you comment on price realization across the 3 sectors, how that's developed in the third quarter and how you anticipate that moving into 2014? That's the first question. And secondly, on Lighting, you said PLS was obviously an important contributor to the operational performance, but you highlighted Europe as the contributor here, rather than, I imagine, Genlyte. And Genlyte was, of course, a big focus in the Capital Markets Day. I believe you said it was back on track. Can you comment on the margin dynamics you saw in Genlyte in 3Q and, again, how you see that progressing into 2014?

Yes, so it's -- you're correct. I said that it was an improvement in the PLS, mainly in Europe. We are working very hard on turning around the former Genlyte business, and that goes as planned. But the real contribution to the results, we'll see from the beginning of next year. That's the expectation. Also, there's so much fundamental work that needs to be done. So the situation in North America is -- with PLS is expected to start improving from that time onwards. This mix impact in PLS really came from our European business. In Healthcare, on price realization, we didn't see a real price erosion outside the 3% to 4% range, at least not what we have in our order book. And that's said to me by the new CFO of Healthcare, Abhijit Bhattacharya, by the way. And in CL and Lighting, there's nothing extraordinary on price decrease that we have seen now this quarter that we hadn't already seen before. So at this moment, no real step-up, let's say, in price erosion movements to the -- to a negative effect.

And just getting back to your Genlyte answer. I mean, clearly, it has around 1.2 billion of sales when you acquired it. Can you try and scale the potential here, as it does start to improve into 2014, in the context of the Lighting margins?

Well, so honestly, it's really a big job to turn it around. We're keenly aware of the necessity and need to do it. We have a very structured plan, Bruno has updated you. And let's say that when we close the year I can give you a better update on what -- how we see the business progressing. But that it will progress and improve, that is, of course, very clear. But it's very hard to quantify that right now.

And just quickly, just to get back on your comment on the pricing. In Lighting, are you seeing an improvement in LED utilization? Is that not driving any improvement in LED pricing there?

Yes, we see improvement in LED, either utilization or uptake. Of course, you have to realize that the consumer uptake of LED is still quite low, and for that, price points need to come further down. We've talked about that also in Capital Markets Day, lower price points that we feel we can make and have roadmaps to drive economic profit out of it. The biggest contributor to the LED business development still remains professional. So then the margins are really driven by mix improvement in solutions, as we have these larger projects that we do. Definitely, there's an undercurrent of improvement. I also really do believe, and we see that, that the eyes on LED have changed already significantly from this is not going to be an industry where everybody can step in, to now, seeing what quota[ph] requirements that there are around LED and this whole thing turning into what we call connected lighting. And I think we gave great examples at Capital Markets Day on how that works in the home and also professionally. But we'll not go too much into this, but we just wanted to make that point.

The next question comes from William Mackie from Berenberg Bank.

It's William Mackie from Berenberg Bank, about 3 questions. First of all, you've reduced the IG&S guidance by approximately 10% for 2013. You -- I think it was 330 down to 290. Could you help us think, given there's a number of exceptionals this year, on what the ongoing IG&S charge or run rate should be as we roll into '14 and onwards? Secondly, you upped the target, I think you mentioned, for Accelerate! You're looking for EUR 1 billion of savings this year as opposed to the EUR 900 million, which I think had been set out. Should we roll that forward through to your 2016 thinking, in which case the EUR 1.6 billion, I think you'd laid out previously, rises arithmetically to the EUR 1.7 billion? And then coming back to Lighting, maybe I'll phrase the question a different way, which I think came earlier. Within PLS, you obviously saw peak margins probably closer to 2007, 2008. How would you characterize the returns that you're generating within PLS currently? And what sort of potential should we expect from that business group within Lighting? François Adrianus van Houten: Maybe I can start with the latter question, William. We expect, over time, as we deal with Genlyte and we are firmly into the solutions territory where we would like to be, and gradually moving more and more towards a direct sales model for the larger projects, and as you recall, we have been investing strongly in sellex in order to set up this large-project sales force, over time, the PLS business needs to get back into double-digit territory. And we think that's possible. It may take some time, but certainly, I have the belief that this business has that potential. The profit pool really will gradually shift from the light source to the lighting application. And we see that we are able to build good control points also in IP in designing these solutions. And I also may want to point out that the LED licensing program is part of the PLS business. On the second one, I can be short. The Accelerate! program savings rate, yes, it's going well. We will hit the EUR 1 billion. But of course, Ron and I already knew that during the Capital Markets Day, and that was part of our plans. It's included in the EUR 1.6 billion timeline to be achieved by 2015. So we will continue to work diligently in driving cost productivity in all the overhead functions. And then we go to the first point, which I am going to lean on Ron, that's the reduced IG&S guidance for this year. But then again, what is it for next year?

Yes. So we said in Q2, 330. So since that time, we had the pension cost inside there. We had some of the IP&S more royalties gains, so the guidance has changed to, let's say, 290 for this year. For next year, it's very difficult to guide right now, but tentatively, I would say that we guide it in Q4, as we always do. So difficult to quantify that right now.

Can I just quickly follow up on Lighting, then, with regard to the restructuring? Again, I think you've guided now for EUR 20 million charge in Q4, which would be substantially below the implied run rate for Lighting of approximately 1.6% of sales for this year. I mean, when you look across the whole of the Lighting division, should we now think that the majority of your major restructuring has been completed, so we're stepping down to a lower level of ongoing repositioning? Or is it just a temporal factor, where you'll be back to more activity into '14? François Adrianus van Houten: Thanks. On Lighting, you need to continue to expect a further rationalization of the installed base of factories. There's more work to be done. And I believe, Ron, we have always given a guidance on the run rate of restructuring in Lighting of approximately 1% to 1.5% on an ongoing basis for the next few years.

Yes, that's correct. So last year was incidentally higher because we had to pull up our plans of rationalizing the conventional footprint. So that's not a real representative year. As Frans said, it's 1% to 1.5%.

The next question comes from Andrew Carter from Royal Bank of Canada.

Most of my questions have actually been answered, but perhaps if I could just ask one on restructuring again. It does look as though the restructuring this year is going to be in the region of about 120. And I was wondering whether -- that's a little bit lower than, I think, we were talking about previously. Do you think that, going into 2014, we should be looking at lower restructuring charges going forward? And the second one was just a quick supplemental just on Healthcare. I wondered if you could talk a little bit about what's going on in Japan, with currency movements there. I think one of your competitors, on Friday, was talking about the Japanese markets having been a bit more difficult for them, and I was wondering what Philips was seeing.

Yes, so we just said that 1.5% for Lighting is in order. In Consumer Lifestyle, there's not a lot, but we always have some ongoing restructuring. The same holds true for Healthcare. Of course, and you've seen it also in the materials that we have distributed, it's in the deck. Let me see, Abhijit, towards the right page here. On Page 31 of the deck, we have basically given an outline of how we see the restructuring related to the overhead cost savings progress, as well as the investments that we are making in improving our IT and process and data landscape to enable the End2End business models to manifest themselves. So that, I would leave it for next year-to-date [ph].

And on Japan?

Sorry, Japan order intake is plus 9% and sales growth is 4%. So even though in a tough environment and with -- yes, with everything that we are doing, we're able to drive this. The sales growth, of course, is as always, on a comparable basis, comparable sales growth. So OIT comparable 9%, sales growth comparable is 4% in Japan, which is an achievement.

The final question comes from Mark Jones from Agency Partners.

Can I just get back to the IG&S guidance? Within that, there's quite a big swing in the IP royalty line. Obviously, there are lots of things that go through that traditional reporting. In the statement, it says a reduction in patent filing costs. Ron, I think you said higher patent income, and I'm not sure if that comes to quite the same thing, but is that just the element that you pointed to as being volatile and probably likely to normalize a little? So that's question one. And then secondly, a slightly more long-term question on Healthcare. Siemens is starting to talk about the need for some strategic reappraisal of their position in that market, given the growing importance of things like biomedicine and data analytics, underlying changes in the nature of the healthcare market. Obviously, you have a different profile to them, but are you happy with your positioning for the evolution of those market trends currently? Was there anything you need to do to broaden your capability within Healthcare on a sort of medium-term view? François Adrianus van Houten: Let me start with Healthcare. And the answer is, yes and yes. I explain that. We are happy with the positioning of our Healthcare sector. Let me remind you that we have 3 legs already. We are in diagnostics, we are in patient monitoring and we are in home healthcare. Now we're also broadening our activities. In diagnostics, we are moving strongly into image-guided minimal intervention, which is the future of surgery. That's a much more higher added-value area, where software applications and new ways to look inside of the body without ripping open the chest is going to revolutionize surgery. That already happens, of course, for cardiology, but it will also apply to oncology. And we think…

Yes. So I guess the question is, how much of that is doable organically, or whether that's something that requires more... François Adrianus van Houten: Good question. Taking you back to the Capital Markets Day guidance, we said that most of our growth is organic. We are reserving more investment money on the one hand, saving 300 to 400 basis points in productivity and, on the other hand, taking 200 basis points of investments. And therefore, it also helps, to a degree, Healthcare. And we don't exclude smaller bolt-on acquisitions. With regard to the IG&S guidance, Ron, do you want to come back on it?

Yes, yes, one comment only. So the difference is mainly because of lower patent filing costs and lower legal cost and litigation cost. So we consider this normal chunkiness. So it's not so much on the income side but more the cost side, that it's better. Okay? François Adrianus van Houten: And then maybe my final point, if I may, before we close the meeting. I'd like to give some recognition to Abhijit Bhattacharya, who sits here doing the last meeting of IR, and then, of course, he's going to be full time the Healthcare CFO. Abhijit, you've done a wonderful job and helped all the people on the phone with all their questions. And maybe I can speak on behalf of all the analysts and investors on the phone, thank you very much.

Thank you very much, Frans. And thank you to all of you on the call. It's been a great ride and which would not have been possible, of course, without my team that I have here, although small but very active. And I want to thank each one of them as well. And I'm sure we will be in touch on various other matters going forward. So thank you very much for that, Frans, much appreciated. François Adrianus van Houten: That's good. Thanks, Abhijit. And of course, as Abhijit moves on, I'm happy to introduce to you -- or announce to you Robin Jansen. Robin will be investor relations as of the 1st of November. He comes to us from DE Masterblenders, and we are very happy to have in him a great replacement. And I'm sure you will all be in touch with him in due course. Thank you.

Thank you.

And this concludes the Royal Philips Third Quarter Results 2013 Conference Call on Monday, 21st of October 2013. Thank you for participating. You may now disconnect.